Moderna agrees to pay nearly $1B to settle Covid vaccine patent battle

Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that comes days before the expected trial start in litigation that has been brewing for years.The cash will go to Arbutus Biopharma and Genevant Sciences, companies in which Roivant Sciences holds ownership stakes. Moderna retains the right to appeal a narr…

Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn

Quick Read Moderna (MRNA) jumped 10% after-hours on a patent settlement of up to $2.25B ($950M upfront), trading at $56.67, up 92.15% YTD. FY 2025 revenue fell 39.23%, operating cash burn was $1.873B, projected end-2026 cash $4.5B-$5B. The patent settlement removes legal uncertainty around Moderna’s COVID vaccine but the $950M upfront payment narrows the company’s cash cushion as it burns through liquidity targeting 2028 breakeven. Are you ah…

Moderna shares rise on $2.25-billion settlement over COVID-19 vaccine technology

Company settles long-running legal battle, shifting focus back to cancer vaccines under development

Moderna Clears Legal Hurdle With $2.25 Billion Patent Settlement

Moderna has agreed to pay up to $2.25 billion to settle a patent dispute over the technology used in its COVID-19 vaccine. The agreement resolves lawsuits filed by Genevant Sciences and Arbutus Biopharma, which accused Moderna of using their lipid nanoparticle delivery technology without authorization, according to Investing.com. Moderna has agreed to pay Roivant up to $2.25 billion to settle claims that the mRNA vaccine developer infringed on R…

Moderna settles COVID vaccine patent dispute for up to $2.25 billion By Investing.com

Moderna settles COVID vaccine patent dispute for up to $2.25 billion

Moderna settles patent lawsuits over COVID vaccine for $950 million

The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.